Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.
Biomira Inc, following its acquisition of ProlX Pharmaceutical Corp, is developing PX-12, an inhibitor of thioredoxin, for the potential treatment of cancer. PX-12 has completed phase I clinical trials.
Galmarini
Carlos M
CM
Université Claude Bernard Lyon 1, EA3737 Pathologie des Cellules Lymphoides, UFR de Médecin Lyon-Sud, Centre Hospitalier Lyon-Sud, 165 Chemin du Grand Revoyet, 69495 Pierre-Bénite, France. carlos.galmarini@recherche.univ-lyon1.fr
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D000075202:Contraindications; D004220:Disulfides / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D013879:Thioredoxins / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D004220:Disulfides; D007093:Imidazoles; D013879:Thioredoxins; C412893:1-methylpropyl-2-imidazolyl disulfide